In patients with DLBCL, increases in FLT3 ligand did not occur until day 8 (mean change +261%, range 16 to 796%), and while in most was resolving by day 22, some patients had persistent elevations (mean change +92%, range −11 to 1280%). Here, FLT3 is linked to diffuse large B-cell lymphoma.